Navigation Links
Wellmune WGP supplementation alleviates

SAN DIEGO, CA. April 9, 2008 Wellmune WGP, a natural immune-enhancing ingredient from Biothera, reduced the incidence of fever and eliminated the need for study subjects to miss work or school due to the cold-like symptoms, researchers reported today at the 2008 Experimental Biology annual meeting.

Don Cox, Ph.D., Vice President of Research & Development for Biotheras Healthcare Group, said, This studys results are exciting because they show the potential for Wellmune WGP to naturally enhance the bodys innate immune response to protect against and ameliorate the symptoms of something that every one of us encountersthe common cold. These results are consistent with numerous other immune health studies conducted with our ingredient, and indicate the real-life benefits that Wellmune WGP supplementation can provide.

The research will be presented at the Poster Sessions starting 9:00 am on April 9th by Douglas Kalman, Ph.D., RD, FACN, a Director at Miami Research Associates, which conducted the study for Biothera. An abstract of the study is available at

The double-blind, placebo-controlled study was conducted during the cold season with 40 healthy subjects, aged 18-65. The subjects were treated daily with either 250mg of Wellmune WGP or a placebo for 90 days. Wellmune WGP is a natural carbohydrate that activates key immune cells, including macrophages and neutrophils, to more quickly recognize and kill foreign challenges. The product engages the bodys natural defenses to promote health, wellness and vitality. In contrast with the placebo group, study participants who received Wellmune WGP daily reported:

  • No incidence of medically verified fever.

  • An increase in general health markers, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2).

  • No need to take a sick day off of work or school (compared with 1.38 days of work/school missed for the placebo group).

In addition, although there were no differences between groups in the number of colds, at the end of the 12-week test period the Wellmune WGP-supplemented group exhibited significant improvements in Physical Component Summary scores as defined in the SF-36v-2 health survey.


Contact: Dave Walsh
Strategic Communications

Post Your Comments:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: